Key result
Tezosentan attenuated pulmonary hypertension but did not improve arterial PO2 or ventilation/perfusion mismatch in a porcine model of acute pulmonary thromboembolism.
Why the study?
Does tezosentan improve hypoxemia and ventilation/perfusion mismatch in a porcine model of acute pulmonary thromboembolism?
Does tezosentan improve hypoxemia and ventilation/perfusion mismatch in a porcine model of acute pulmonary thromboembolism?
Endothelin receptor blockade with tezosentan does not improve hypoxemia or ventilation/perfusion mismatch in acute pulmonary embolism, despite attenuating pulmonary hypertension.
Does not support endothelin blockade for hypoxemia in acute PE; hypothesis-generating and requires validation in other models before clinical consideration.
We studied the roles of endothelins in determining ventilation (Va) and perfusion (Q) mismatch in a porcine model of acute pulmonary thromboembolism (APTE), using a nonspecific endothelin antagonist, tezosentan. Nine anesthetized piglets (approximately 23 kg) received autologous clots (approximately 20 g) via a central venous catheter at time = 0 min. The distribution of Va and Q at five different time points (-30, -5, 30, 60, 120 min) was mapped by fluorescent microspheres of 10 different colors. Five piglets (group 1) received tezosentan (courtesy of Actelion) starting at time = 40 min for 2 h, and four piglets (group 2) received only saline and served as control. Our results showed that, in all of the animals at 30 min following APTE but before tezosentan, the mean Va/Q was increased, as was Va/Q heterogeneity (log SD Va/Q), which represented a widening of its main peak. Afterwards, tezosentan attenuated the pulmonary hypertension in group 1 but also produced moderate systemic hypotension. However, it did not improve arterial PO2 or Va/Q mismatch. We concluded that endothelin antagonism had minimal impact on gas exchange following APTE and confirmed our earlier observation that the main mechanism for hypoxemia in APTE was due to the mechanical redistribution of pulmonary regional blood flow away from the embolized vessels, resulting in the creation of many divergent low and high Va/Q regions.
No takes yet. Share an insight, caveat, or question.
Tsang et al. (2006) studied Acute pulmonary thromboembolism (n=9). Tezosentan vs. Saline was evaluated on Ventilation (Va) and perfusion (Q) mismatch and arterial PO2. Tezosentan attenuated pulmonary hypertension but did not improve arterial PO2 or ventilation/perfusion mismatch in a porcine model of acute pulmonary thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: